WHO ICTRP trial
A single-arm Phase II clinical study to evaluate the efficacy and safety of…
ChiCTR2200060876 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2200060876 |
|---|---|
| Public title | A single-arm Phase II clinical study to evaluate the efficacy and safety of carrelizumab combined with platinum-containing two-drug chemotherapy after induction therapy with concurrent chemoradiotherapy and maintenance of carrelizumab in the treatment of inoperable stage III non-small cell lung cancer |
| Scientific title | A single-arm Phase II clinical study to evaluate the efficacy and safety of carrelizumab combined with platinum-containing two-drug chemotherapy after induction therapy with concurrent chemoradiotherapy and maintenance of carrelizumab in the treatment of inoperable stage III non-small cell lung… |
| Primary sponsor | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Treatment study |
| Phase | 2 |
| Countries | China |
| Conditions | lung cancer |
| Interventions | group1:carrelizumab |
| Registration date | Jun 13, 2022 |
| Target size | group1:48 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: